Near shore protein (688137.SH): High-throughput wet experiments and data packet services that enable AI are still in the early stages of market expansion

Zhitongcaijing · 2d ago

Zhitong Financial App News, Near Shore Protein (688137.SH) issued a notice on serious abnormal stock trading fluctuations and risk alerts, stating that the company's revenue from RNA vaccine drug-related products in 2025 accounted for 11.38% of total product revenue (see 2025 Annual Report for details), which is relatively low.

The company's high-throughput wet testing and data package services that enable AI are still in the early stages of market expansion. As of the first half of 2026, related business revenue accounted for less than 2% of the company's overall revenue. Given that the application of AI in the drug development industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulties in commercialization, and there is significant uncertainty about the company's future revenue and profit delivery.